BioCardia to Present at 2015 Stem Cell Meeting on the Mesa

October 06, 2015

SAN CARLOS, CA (GlobeNewswire) – BioCardia, Inc., a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases announced today that Peter Altman, Chief Executive Officer will present at the annual Partnering Forum of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, California.

Event:

2015 Stem Cell Meeting on the Mesa – Partnering Forum

Date: 

October 07, 2015

Time: 

1:30 p.m. PDT

Location: 

Estancia La Jolla Hotel & Spa
9700 North Torrey Pines Road, La Jolla, CA 92037

A live video webcast will be available here. Please visit this site for full information.

This conference brings together senior executives and top decision makers in the industry within the scientific community with the shared goal of advancing and translating cutting-edge research into revolutionary treatments and cures.


About BioCardia, Inc.
BioCardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ cell therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. These programs are enabled by the Company's Helix™ transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.

Contact:
Miranda Peto Benvenuti MPeto@BioCardia.com

News

28 Oct

Cardiology Today

Ongoing trial assessing novel assay to determine response to cardiac regenerative therapy
Read More
11 May

University of Minnesota

Investigational Therapy Exploring Treatment of Heart Failure Seeks to Stimulate Body’s Natural Healing Response
Read More
16 Apr

Saint Joseph Mercy

St. Joseph Mercy Ann Arbor to perform clinical trial using stem cells to treat congestive heart failure
Read More
31 Jan

BioWorld Med Tech

Biocardia wins IDE for cell therapy as treatment for angina
Read More
03 Oct

BioWorld Med Tech

Biocardia presses on with Cardiamp pivotal trial to treat patients with heart failure
Read More
26 May

Med Latest

BioCardia® Helix Results in Higher Stem Cell Retention in Myocardium
Read More

press releases

07 Aug
2019 BioCardia Announces Issuance of European Patent for Breakthrough Diagnostic Assay for Patient Selection Prior to Cardiac Cell Therapy Delivery
06 Aug
2019 BioCardia Announces Closing of $10.0 Million Public Offering
02 Aug
2019 BioCardia Announces Pricing of $10.0 Million Public Offering and Uplisting to NASDAQ
25 Jul
2019 BioCardia Signs Exclusive Development Agreement with AstraZeneca
12 Jun
2019 BioCardia Announces Issuance of Chinese Patent for Image-Guided Biotherapeutic Delivery
06 Jun
2019 BioCardia Announces Reverse Stock Split and Plan for Listing on a Major Stock Exchange
Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS